Gilead Sciences HIV/AIDS Drug Patents
In March 2007, PUBPAT filed formal requests with the United States Patent and Trademark Office challenging four key HIV/AIDS drug patents held by Gilead Sciences, Inc. (NASDAQ: GILD). As part of its requests, PUBPAT submitted prior art that the Patent Office did not review before granting the patents to the Foster City, California, biopharmaceutical giant. PUBPAT also explained how the submitted prior art invalidates the patents and asked that the Patent Office undertake a review and revoke them. In July 2007, the Patent Office granted each of PUBPAT's requests and ordered reexamination of all four patents. In December 2007 and January 2008, the Patent Office rejected all of the claims of each of the patents.
Related Documents
- Patent Office Order Rejecting All Claims of '695 Patent (PDF; 622KB)
- Patent Office Order Rejecting All Claims of '946 Patent (PDF; 1.4MB)
- Patent Office Order Rejecting All Claims of '089 Patent (PDF; 485KB)
- Patent Office Order Rejecting All Claims of '230 Patent (PDF; 615KB)
- Patent Office Order Granting Reexamination of '695 Patent (PDF; 596KB)
- Patent Office Order Granting Reexamination of '946 Patent (PDF; 447KB)
- Patent Office Order Granting Reexamination of '089 Patent (PDF; 485KB)
- Patent Office Order Granting Reexamination of '230 Patent (PDF; 519KB)
- PUBPAT Request for Reexamination of U.S. Patent No. 5,922,695 (PDF; 560KB)
- PUBPAT Request for Reexamination of U.S. Patent No. 5,935,946 (PDF; 520KB)
- PUBPAT Request for Reexamination of U.S. Patent No. 5,977,089 (PDF; 486KB)
- PUBPAT Request for Reexamination of U.S. Patent No. 6,043,230 (PDF; 494KB)
Related News
- January 23, 2008: U.S. PATENT OFFICE REJECTS KEY HIV/AIDS DRUG PATENTS AT PUBPAT REQUEST: Government Finds Prior Art Submitted by PUBPAT Invalidates All of Gilead Sciences' Claims
- July 18, 2007: KEY HIV/AIDS DRUG PATENTS TO BE REVIEWED BY U.S. PATENT OFFICE: Prior Art Submitted by PUBPAT Raises Substantial Doubt Regarding Validity of Gilead Sciences Claims
- March 26, 2007: PUBPAT TAKES ON KEY HIV/AIDS DRUG PATENTS: Non-Profit Submits Prior Art to U.S. Patent Office and Asks For Revocation of Four Gilead Sciences Patents